The main GLP-1 medications are semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide, plus the dual agonist tirzepatide and the newer oral agent orforglipron. Several of these carry more than one brand name because the same molecule is approved separately for type 2 diabetes and for weight management. That is the single fact that makes any list confusing: one drug can appear three times under three different names. This guide sorts them by molecule, then by what they actually do.
What does a GLP-1 drug do?
GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after eating. It prompts insulin release when blood sugar rises, slows how fast the stomach empties, and dampens appetite signals in the brain. Drugs that copy or extend this hormone were built first for type 2 diabetes and later found to produce meaningful weight loss. A review of how these agents work, including the dual agonists that add a second receptor target, is set out in the pharmacology literature on GLP-1 and GIP receptor mechanisms.
That double history is why the same molecule shows up in a diabetes aisle and a weight-management aisle. The receptor is the same. The approved use, the dose, and the brand name are not.
Which single-agent GLP-1 drugs exist?
Start with the pure GLP-1 receptor agonists, the drugs that act on one receptor.
Semaglutide is the most familiar. It is sold as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral tablet for diabetes. Same molecule, three names.
Liraglutide came earlier, given as a daily injection. It is marketed as Victoza for diabetes and Saxenda for weight management.
Dulaglutide (Trulicity) is a once-weekly injection for type 2 diabetes. Exenatide (Byetta, and the extended-release Bydureon) was one of the first agents in the class. Lixisenatide (Adlyxin) rounds out the older injectables and is used less often now.
The practical split is dosing frequency and approved use. Weekly agents have largely displaced daily ones for convenience, and the weight-management approvals sit mostly with semaglutide and liraglutide rather than the older diabetes-only drugs.
See also: 9 GLP-1 Subscription Services Ranked for People Who Actually Want Answers
Where do the dual agonists fit?
Tirzepatide is the drug that broke the single-receptor mold. It targets both the GIP and the GLP-1 receptor, which is why it is often described as a dual agonist rather than a plain GLP-1 drug. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management. The molecule’s early development, from discovery through its first proof-of-concept trial in type 2 diabetes, is documented in the LY3298176 report.
Adding the second receptor appears to matter clinically. In head-to-count terms tirzepatide has produced some of the largest average weight reductions seen in the class, though comparing across separate trials is not the same as a direct contest between drugs, and readers should be careful not to treat one study’s numbers as a verdict against another.
Is there really a GLP-1 pill now?
Yes, and this is the part of the list that changed most recently. Oral semaglutide (Rybelsus) has existed for years, but it is a peptide that needs an absorption agent and careful dosing timing. The bigger shift is orforglipron, a small-molecule GLP-1 receptor agonist that can be taken as a daily pill without those restrictions. Its early trial in adults with obesity showed substantial weight loss with a phase-appropriate safety profile, and a later obesity treatment analysis expanded on those findings.
Orforglipron was FDA-approved in 2026 for weight management under the brand FOUNDAYO. That approval is a genuine milestone, since it is the first oral small-molecule agent in the group to clear the process, as summarized in its first-approval writeup. It is not investigational anymore, and it should not be described that way.
How do the main GLP-1 drugs compare?
| Molecule | Brand names | Form and schedule | Receptor target |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Weekly injection or daily tablet | GLP-1 |
| Liraglutide | Victoza, Saxenda | Daily injection | GLP-1 |
| Dulaglutide | Trulicity | Weekly injection | GLP-1 |
| Tirzepatide | Mounjaro, Zepbound | Weekly injection | GIP and GLP-1 |
| Orforglipron | FOUNDAYO | Daily tablet | GLP-1 (small molecule) |
What is still investigational?
The class is not finished growing. Retatrutide, a triple agonist targeting GLP-1, GIP, and the glucagon receptor, is still in clinical trials and has no approved product. Early data have drawn a lot of attention, but investigational means investigational: the safety and effectiveness picture is not settled, and it cannot be prescribed as an approved drug. Treat any promotion of it as premature.
Where does compounded GLP-1 sit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than manufactured under an approved application. They are not FDA-approved products, and they have not been through the process that generated the trial evidence for the branded versions. That distinction is real, not a formality. What compounded routes tend to offer is a flat cash price without insurance in the loop, which is why they surfaced during brand shortages and why some people still ask about them.
If cost or access is the sticking point, it is worth comparing the legitimate routes side by side rather than defaulting to the first ad you see. Direct programs from makers such as LillyDirect and NovoCare, telehealth prescribers like Ro, Hims and Hers, and Henry Meds, and physician-supervised practices are all in the field. For readers weighing where compounded options fit among approved drugs, FormBlends’ guide lays out the named agents alongside clinician-supervised pricing, which makes the trade-offs easier to see before a decision point. The honest summary is that compounded medication trades regulatory assurance for cost predictability, and that trade belongs with a prescriber who knows the case.
Which drug should someone actually pick?
That is a clinical question, not a ranking. Current obesity pharmacotherapy guidance, including the 2025 clinical practice guideline update and the AGA guideline on pharmacological interventions, frames these drugs as tools chosen against a person’s conditions, not as a leaderboard. Diagnosis matters too, and the work on defining clinical obesity argues for looking past body mass index alone. For people with metabolic liver disease, the EASL guidance on MASLD is relevant to how these agents are weighed.
Key takeaways
- One molecule can carry several brand names, so a long list is often fewer actual drugs.
- Tirzepatide is a dual GIP plus GLP-1 agonist, not a single-receptor GLP-1 drug.
- Orforglipron (FOUNDAYO) is an approved oral option as of 2026; retatrutide is not approved.
- Compounded versions are not FDA-approved products, whatever molecule they contain.
- Drug choice is a clinical decision guided by conditions, not by a single effectiveness figure.
Frequently asked questions
How many GLP-1 drugs are actually on the market?
A handful of approved single-agent GLP-1 drugs, one approved GIP plus GLP-1 dual agonist, one recently approved oral small-molecule agent, and several investigational compounds still in trials. The exact count depends on whether you separate a molecule by its brand names and approved uses.
Are GLP-1 drugs for diabetes or weight loss?
Both, depending on the specific product. Several molecules carry separate brand names and separate approvals for type 2 diabetes and for chronic weight management, even when the active drug is the same.
Is tirzepatide a GLP-1 drug?
It acts on the GLP-1 receptor, but it is a dual agonist that also targets the GIP receptor. That is why it is often grouped with GLP-1 drugs while being described more precisely as a GIP plus GLP-1 receptor agonist.
Is there a GLP-1 pill?
Yes. Oral semaglutide has been available, and orforglipron, an oral small-molecule GLP-1 receptor agonist, was approved for weight management in 2026 under the brand FOUNDAYO.
Is compounded GLP-1 the same as the brand drug?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may contain the same active molecule, but they have not been through the approval process that produced the published trial evidence.
